Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 62, Issue 10, 2005, Pages 1048-1052

  Strum, Matthew W ^a   Hopkins, Robert ^b   West, Donna S ^c,e   Harris, Brittany N ^d  

^a ASTRAZENECA   (United Kingdom)

^b Department of Internal Medicine and Pediatrics

^c Department of Pharmacy Practice   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antidiabetic agents; Charity; Diabetes mellitus; Drug use; Industry, pharmaceutical; Outcomes; Prescriptions; Sociology

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; EUROPEAN AMERICAN; FEMALE; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL EDUCATION; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WILCOXON SIGNED RANKS TEST;

EID: 18744392541     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.10.1048     Document Type: Article

References (33)

1. Chisholm MA, DiPiro JT. Pharmaceutical manufacturer assistance programs. Arch Intern Med. 2002; 162:780-4.
2. Chisholm MA, Reinhardt BO, Vollenweider LJ et al. Medication assistance programs for uninsured and indigent patients. Am J Health-Syst Pharm. 2000; 57:1131-6.
3. Member company patient assistance program survey. 2003. Washington, DC: PhRMA; 2003 Nov.
4. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998; 21:179-82.
5. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation. 1999; 100:1132-3.
6. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician. 1999; 59:2835-44,2849-50.
7. Riddle MC. Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999; 60:2613-20.
8. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 283:1695-702.
9. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-9):1-25.
10. Arauz-Pacheco C, Parrott MA, Raskin P et al. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(suppl 1):S80-2.
11. Grant RW, Cagliero E, Murphy-Sheehy P et al. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 2002; 112:603-9.
12. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997; 20:735-44.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
14. Piette JD, Wagner TH, Potter MB et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004; 42:102-9.
15. Paris W, Dunham S, Sebastian A et al. Medication nonadherence and its relation to financial restriction. J Transpl Coord. 1999; 9:149-52.
16. Tafreshi MJ, Melby MJ, Kaback KR et al. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999; 33:1252-7.
17. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990; 150:841-5.
18. Schoen MD, DiDomenico RJ, Connor SE et al. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy. 2001; 21:1455-63.
19. Nykamp D, Ruggles D. Impact of an indigent care program on use of resources: experiences at one hospital. Pharmacotherapy. 2000; 20:217-20.
20. National Institute for Health Care Management Research and Educational Foundation. Prescription drug expenditures in 2001: another year of escalating costs. www.nihcm.org/spending 2001.pdf (accessed 2004 Jun 2).
21. Mueller C, Schur C, O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997; 87:1626-9.
22. Soumerai S, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees - a call to action. N Engl J Med. 1999; 340:722-8.
23. Hadley J, Holahan J. The cost of care for the uninsured: what do we spend, who pays, and what would full coverage add to medical spending? May 10, 2004. www.kff.org/uninsured/loader.cfm? url=/commonspot/security/getfile. cfm&PageID=35965 (accessed 2005 Feb 8).
24. Weissman JS, Gastonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA. 1992; 268:2388-94.
25. Grant RW, Pirraglia PA, Meigs JB et al. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med. 2004; 164:1134-9.
26. National Pharmaceutical Council. A closer look at diabetes: a joint project between the American Diabetes Association and the National Pharmaceutical Council. www.npcnow.org/resources/PDFs/CL_Diabetes.pdf (accessed 2004 Jul 15).
27. Weiner S, Dischler J, Horvitz C. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program. Am J Health-Syst Pharm. 2001; 58:146-50.
28. Coleman CI, Reddy P, Quercia RA et al. Cost-benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients. Am J Health-Syst Pharm. 2003; 60:378-82.
29. Chisholm MA, Vollenweider LJ, Mulloy LL et al. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic. Clin Transpl. 2000; 14:304-7.
30. Decane BE, Chapman J. Program for procurement of drugs for indigent patients. Am J Hosp Pharm. 1994; 51:669-71.
31. Hotchkiss BD, Pearson C, Lisitano R. Pharmacy coordination of an indigent care program in a psychiatric facility. Am J Health-Syst Pharm. 1998; 55:1293-6.
32. Figueroa Z, Harkins L, Sloan S. Clinical and economic impact of pharmacy services in a low-income family practice clinic within a community hospital setting. Hosp Pharm. 2004; 39:346-50.
33. Harmon GN, Lefante J, Roy W et al. Outpatient medication assistance program in a rural setting. Am J Health-Syst Pharm. 2004; 61:603-7.